Company Overview and News
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
HRT MGG HRTFF MMRGF GFI.WI FNV NEM NMKEF RSG PRB RNX RNKLF KGC NMX RMGGF FQVLF AEM MACIF AG FQM GFIOF NDM WPM RPM FR SAND FNV.WT.A SSL GPL SDDXF ALO PROBF K RPMGD WHGOF RPMGF SNXZF ORG RGLD RNX.WT RMGGY GFI PGLC CANWF FNV RGL
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 4 TO THE PROSPE
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 5 TO THE PROSPE
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 6 TO THE PROSPE
Chicago, IL – May 31, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Harmony Gold Mining Company Ltd. (HMY - Free Report) , NovaGold Resources Inc. (NG - Free Report) , Pretium Resources Inc. (PVG - Free Report) and Pershing Gold Corp. (PGLC - Free Report) .
HMY TXN MATW PVG NG ALIMR IMMR PVG DG XOXO XOMA PGLC HGMCF
Though the market for gold will remain strong for years to come given the demand for jewelry, bars and coins as well as its safe-haven appeal, it has a number of threats lurking. Below, we have discussed some of the key challenges and what investors in the sector should be wary of in the coming months and years.
HMY WFC WFCNP WFC.WS WFC.PRL PVG WFC.PRJ NG WFC.PRT WFC.PRR PVG WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX PGLC HGMCF WFC.PRW WFC.PRV
Per the data available from the World Gold Council, global demand for gold declined 7% year over year to 973.5 tons in the first quarter of 2018 — the weakest first quarter in 10 years. The weak performance can primarily be attributed to a fall in investment demand for gold bars and gold-backed ETFs, partly due to range-bound gold prices. Let’s delve deeper and analyze the factors that led to the decline and also find out what is in store for the yellow metal.
HMY SAND SSL SDDXF PVG K SNXZF NG PVG KGC PGLC IAG HGMCF FNV
UNITED STATES SECURITIES AND EXCHANGE
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 2
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 3
Filed Pursuant to Rule 424(b)(3) Registration No. 333-222612 PROSPECTUS SUPPLEMENT NO. 1 TO THE PROSPECTUS DATED
We see multiple red flags with Aphria’s proposed purchase of Nuuvera, a company that was incorporated in January '17 and had revenue of only ~$30k from inception to September '17.
RIOT NUUVF VRX CXRX VRX MARA APHQF BIOP PGLC
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to PGLC / Pershing Gold Corporation on message board site Silicon Investor.
as of ET